-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Teva Pharmaceutical Industries Ltd annual/quarterly Deferred Income Tax Expense (Benefit) history and growth rate for Q1 2010.
- Teva Pharmaceutical Industries Ltd Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2010 was $0.000.
- Teva Pharmaceutical Industries Ltd annual Deferred Income Tax Expense (Benefit) for 2023 was -$340M, a 68.3% increase from 2022.
- Teva Pharmaceutical Industries Ltd annual Deferred Income Tax Expense (Benefit) for 2022 was -$1.07B, a 1719% decline from 2021.
- Teva Pharmaceutical Industries Ltd annual Deferred Income Tax Expense (Benefit) for 2021 was -$59M, a 83.1% increase from 2020.
Deferred Income Tax Expense (Benefit), Quarterly (USD)